Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of preservative-free inactivated split influenza vaccine (2005/2006 strain composition)
2005-000430-20Phase 3Completed
- Sponsor
- Chiron Behring Vaccines
- Start
- May 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of inactivated influenza vaccine (split virion) in influenza, sponsored by Chiron Behring Vaccines. Primary endpoints: Immunogenicity assessed by hemagglutination inhibition titers at Day 21 and Safety and tolerability. Started May 2005; status: completed.
02
Drugs
inactivated influenza vaccine (split virion)
03
Conditions
influenza
Beyond the preview
Go deeper on 2005-000430-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000430-20.